Plain-English translation of NCT05783323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing larotrectinib, a targeted drug that blocks a specific genetic abnormality found in some thyroid cancers. The goal is to see if taking this medication for 6 months can prepare the cancer to respond better to radioactive iodine therapy, a standard treatment. Researchers will measure how well the treatment shrinks lung tumors over 18 months.
Some thyroid cancers have a genetic change (called an NTRK fusion) that makes them resistant to standard radioactive iodine therapy. This trial is testing whether the medication can 'wake up' the cancer cells so they become responsive to radioactive iodine again, potentially offering patients a better chance of controlling their disease.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth every day for 6 months, with regular clinic visits and blood tests to monitor your health and how well the treatment is working. After 6 months, you would receive radioactive iodine therapy at a hospital, continue taking the medication for 5 more days, and then stop treatment to allow your doctors to observe how your cancer responds over the following months. The total study period focuses on measuring your cancer's response at the 18-month mark.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States